Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/25/2025

Management of Supraventricular and Ventricular Extrasystoles

Initial Evaluation and Treatment

  • The American College of Cardiology recommends that most extrasystoles are benign and do not require antiarrhythmic treatment, but underlying structural heart disease should always be ruled out through echocardiography, as this radically changes the therapeutic approach and prognosis 1
  • An ECG should be performed to classify extrasystoles as supraventricular or ventricular 1
  • Echocardiography is mandatory to evaluate ventricular function and structural heart disease 1
  • Benign extrasystoles typically decrease with exercise and are more noticeable at rest 1
  • Patients describe extrasystoles as pauses or skipped beats followed by a strong beat 1
  • Eliminating triggering factors (caffeine, alcohol, stress) is the first-line treatment for symptomatic patients 1
  • This intervention should be attempted before any pharmacological therapy 1
  • If lifestyle modifications are insufficient, beta-blockers should be considered for symptomatic control 1
  • Beta-blockers are the first-line pharmacological option for symptomatic supraventricular extrasystoles 1
  • Vagal maneuvers (Valsalva, carotid sinus massage) can terminate up to 25% of paroxysmal supraventricular tachycardias 2
  • Teaching vagal maneuvers is recommended if supraventricular extrasystoles trigger episodes of paroxysmal supraventricular tachycardia 1, 2

Special Considerations

  • Never initiate antiarrhythmic treatment with Class I or Class III drugs without documented arrhythmia due to the risk of proarrhythmia 1
  • This is an absolute contraindication that can cause more harm than benefit 1
  • Antiarrhythmic treatment has a purely symptomatic role and does not offer prognostic benefit 1
  • Aggressive rhythm control is needed when frequent extrasystoles cause tachycardia-induced cardiomyopathy 1
  • Ventricular dysfunction correlates with the duration and frequency of the arrhythmia 1
  • Cardiomyopathy is reversible with effective treatment of the arrhythmia 1
  • Beta-blockers can be prescribed empirically as long as significant bradycardia (<50 bpm) has been excluded 1
  • Basal heart rate should be verified before initiating beta-blockers 1

Pharmacological Treatment

  • Flecainida should not be administered to patients with significant ventricular dysfunction 3
  • Blockers of the AV node (adenosine, beta-blockers, calcium antagonists, digoxin) should not be used in patients with Wolff-Parkinson-White syndrome and preexcitation 2